Whalen Wealth Management Inc. Acquires 7,942 Shares of Abbott Laboratories $ABT

Whalen Wealth Management Inc. raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 217.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,586 shares of the healthcare product maker’s stock after buying an additional 7,942 shares during the quarter. Abbott Laboratories comprises approximately 0.8% of Whalen Wealth Management Inc.’s holdings, making the stock its 28th largest position. Whalen Wealth Management Inc.’s holdings in Abbott Laboratories were worth $1,452,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the 3rd quarter worth about $31,000. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories during the second quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Barclays decreased their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Oppenheimer dropped their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Citigroup cut their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $135.68.

Abbott Laboratories Stock Down 0.0%

Abbott Laboratories stock opened at $102.84 on Friday. The business’s 50-day moving average price is $109.48 and its 200 day moving average price is $121.11. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm has a market cap of $179.11 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 52 week low of $100.88 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last quarter. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.